PPT-Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?
Author : tatyana-admore | Published Date : 2018-11-08
Expert Panelists Program Goals Evaluating CV Risk in New Antidiabetic Therapies FDA Guidance EXAMINE and SAVORTIMI 53 EXAMINE New Analyses SAVORTIMI 53 Saxagliptin
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Emerging CV Outcomes Trial Results: What..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?: Transcript
Expert Panelists Program Goals Evaluating CV Risk in New Antidiabetic Therapies FDA Guidance EXAMINE and SAVORTIMI 53 EXAMINE New Analyses SAVORTIMI 53 Saxagliptin in Patients With T2D and History ofat Risk for CV Events. Brett Galambos. . – Waldheim. Colleen Murphy - Delmas. Waldheim Canola Variety Trial. Swath Date: August 23. . All varieties EXCEPT. Swath Date: August 27. Canterra 1970. Nexera 1012 RR. Nexera 1016 RR. Emily Lorino. Coordinator for Leadership Development. NASPA-FL Drive-In . October 3, 2014. Corinne Olsen. Student Government Director for Leadership. Overview. History of the Office of Multicultural & Leadership Development. Scale in Iowa. Tracy Blackmer. Peter Kyveryga. www.isafarmnet.com. Advancing Agricultural Performance. ®. . 1. Iowa Soybean Association . On-Farm Network® . Precision Ag Tools. 2. .. The high price of nitrogen fertilizer/grain combined with the complexity of N dynamics makes it desirable to improve N management.. Agenda. Managing RA: Current Successes and Unmet Needs. Introduction. Evolution of RA Treatments Over Time. Reductions in Joint Damage, Need for Joint Replacement Surgery. Effective Agents Have Reduced the Elevated Risk of Mortality Associated With RA. Strategy, Measurement & Evaluation . © Bill & Melinda Gates Foundation |. INTRODUCTION. The foundation has . streamlined the . process . and approach we use for . making and managing . investments, both grants and contracts. . Strategy, Measurement & Evaluation . © Bill & Melinda Gates Foundation |. INTRODUCTION. The foundation has . streamlined the . process . and approach we use for . making and managing . investments, both grants and contracts. . Susan S. . Ellenberg. , Ph.D.. University of Pennsylvania. SCT/ICTMC Joint Meeting. Liverpool, UK. May 8, 2017. CLINICAL TRIALS TIMELINE. 1948: First randomized clinical trials of modern era. 1962: Amendments to U.S. Food, Drug and Cosmetic Act requiring demonstration of efficacy as well as safety. A RANDOMIZED CONTROLLED. CLINICAL TRIAL. REPRODUCIBILITY IN RESEARCH. “Growing alarm about results that cannot be reproduced” . . Nature Supplement, Challenges in Irreproducible Research, October 7, 2015. This program will include a discussion . of investigational agents not approved . by the FDA for use in the United States.. RA Pathobiology. Therapeutic Targets in RA. JAK/STAT Pathway: Communication From Transmembrane Receptors to the Nucleus. CLINICAL TRIALS IN THE TWENTY-FIRST CENTURY: ONGOING CHALLENGES AND EMERGING ISSUES Susan S. Ellenberg , Ph.D. University of Pennsylvania SCT/ICTMC Joint Meeting Liverpool, UK May 8, 2017 CLINICAL TRIALS TIMELINE Susan S. . Ellenberg. , Ph.D.. University of Pennsylvania. SCT/ICTMC Joint Meeting. Liverpool, UK. May 8, 2017. CLINICAL TRIALS TIMELINE. 1948: First randomized clinical trials of modern era. 1962: Amendments to U.S. Food, Drug and Cosmetic Act requiring demonstration of efficacy as well as safety. J from clinical trials Signatories on 18 May 2017 The Canadian Institutes of Health Research (CIHR) (joined on 28 October 2020) Health Research Council of New Zealand (joined on 27 July 2020) Euro T. he . trial sponsor . compiles . a detailed clinical study report (CSR. ) after each clinical trial. . This report follows . a format laid down by the regulatory . authorities.. The CSR can be hundreds of pages long.. Tony Durkee, PhD. Coordinator for Clinical Trial Reporting. Compliance & Data Office (CDO), Research Support Office (RSO). Karolinska . Institutet. (KI). Email: tony.durkee@ki.se. . 6/17/2021. Tony Durkee.
Download Document
Here is the link to download the presentation.
"Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents
